In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AngioDynamics shares drop after profit warning

This article was originally published in Clinica

Executive Summary

Shares in vascular disease treatment specialist AngioDynamics plummeted on the Nasdaq Stock Exchange after the company lowered its sales targets for fiscal 2008. The company updated its revenue guidance from $170-175m to $165-167m to reflect the disappointing preliminary third-quarter results. It reported that its 10% growth in sales of its interventional product lines during the period was "less than expected". AngioDynamics also reported that while its SmartPort CT technology saw healthy sales, dialysis product sales were impacted by price competition.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts